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Smoking cessation research today is dominated by the development and evaluation of interventions 
to improve the odds of quitting successfully. Yet little attention has been paid to the large majority of 
ex-smokers who quit without recourse to any formal assistance. To many, these unassisted quitters 
are of little interest other than as a comparator population against which to test the efficacy or 
effectiveness of pharmaceutical or behavioural interventions. The effect of this neglect is 
compounded by the preference for reporting intervention success as rates rather than as the 
numbers of ex-smokers generated across populations through such interventions. In so doing, 
researchers have insulated those in policy and practice from the importance of unassisted smoking 
cessation and the unparalleled contribution it has and will continue to make to reducing smoking 
prevalence.  
In 1955, five years after Wynder and Graham’s historic study of smokers and lung cancer was 
published in JAMA,
1
 7.7 million Americans  (6.4% of the population) were former smokers. Ten years 
later, following widespread publicity surrounding the 1964 US Surgeon General’s Report, the number 
of ex-smokers had ballooned to 19.2 million (13.5%) ex-smokers. By 1975, 32.6 million Americans 
(19.4%) had stopped smoking.
2
 In 1979, the then director of the US Office on Smoking and Health 
noted in a National Institute of Drug Abuse Monograph  “In the past 15 years, 30 million smokers 
have quit the habit, almost all of them on their own.” 
3
 Many of these quitters had been very heavy 
smokers. 
The same monograph also stated that: “longitudinal studies should be designed to 
investigate the natural history of spontaneous quitters ... We know virtually nothing about such 
people or their success at achieving and maintaining abstinence”
3
 Thirty-five years later, very little has 
changed about that ignorance: knowledge of mass smoking cessation across 50 years reflects the 
“inverse impact law of smoking cessation”.
4
 Far more is known about the “tail” of people who quit 
smoking via pharmacological and professionally mediated interventions than about the mass  “dog” 
of ex-smokers who continue to quit unassisted.  
Yet smoking cessation research has its roots in unassisted cessation. In the 1970s and 1980s, 
those grappling with why success rates for therapy seekers were no better than those for self-quitters 
turned their attention studying those who quit on their own.
5
 As a population, self-quitters were 
thought to hold the answers to the problem of smoking cessation. Studies throughout the 1970s and 
1980s lead to the identification of strategies that successful self-quitters employed, and these 
approaches occasionally informed the design of both individual and mass-reach interventions.  
 2 
In 1988, understanding of the effects of nicotine on the central nervous system and on the 
ability of nicotine replacement therapy (NRT) to mitigate withdrawal prompted the widespread belief 
that moderating withdrawal reactions would facilitate quitting. Four years later, a review of smoking 
cessation concluded that in light of this new knowledge, “what is required is a broader perspective 
and greater respect for the limited role of individual and even small group interventions. Over the 
past decade we have witnessed a sometimes grudging acknowledgement of and interest in the 
pharmacological aspects and addictive properties of tobacco.”
6
 Psychologists wedded to clinical 
models were making way for what they saw as the first potentially mass-reach effective approach to 
cessation. 
Twenty-five years after tobacco use was officially labeled as an addiction and NRT heralded 
as the first big hope for smoking cessation, it is time to take stock of cessation pharmacotherapy. It 
appears that this ‘treatable condition’ is not responding as hoped either to NRT or to the prescription 
smoking cessation medications bupropion or varenicline that followed.
7
 Sadly, it remains the case 
that by far the most common outcome at 6 to 12 months after using such medication in real-world 
settings is continuing smoking. Undoubtedly, much smoker resistance to using cessation medication is 
due to many smokers learning from other smokers that real-world experience of using these drugs 
does not produce outcomes that remotely compare with benchmarks for other drugs they use for 
other purposes. Few, if any, other drugs for any purpose with such records would ever be prescribed. 
Despite massive publicity and (in some nations) subsidies given to NRT, bupropion and 
varenicline during these decades, the additional tens of millions of persons (or hundreds of millions 
globally) who quit smoking in this time continued to dominantly include those who quit without 
pharmacological or professional assistance.
8,9
 For the congenitally optimistic this is perennially 
explained as sub-optimal reach or dissemination, with the solution being to facilitate greater access to 
assistance, improve smoker knowledge about the benefits of assistance, or further individualise 
treatment.  However, after nearly three decades of pharmaceutical industry’s turbo-charged effort to 
increase physician engagement and erode population resistance to pharmaceutical-based cessation, 
can there be any more serious rabbits left in that hat? 
It has been argued that NRT and smoking cessation medications are less effective under real-
world conditions than in research trials.
7
 In Australia, data on the real-world experiences of 
varenicline indicate stark differences from experiences under research conditions.
7
 For example, 
adherence is far lower: in Australia, 44–50% of patients who received subsidised prescriptions for 
varenicline failed to commence the last 8 weeks of treatment (no data were available to indicate 
what proportion of the remainder completed the last 8 weeks of treatment) in contrast to 12-week 
completion rates of 68–76% in clinical trials. Yet between January 2008 and October 2009, the 
Australian government spent $93 million on varenicline prescriptions. This compares with $59 million 
allocated over four years to social marketing campaigns designed to promote quit attempts in 
Australia. Given this relatively high spending on pharmacotherapy, it is essential that we are realistic 
about its potential impact on population smoking prevalence and whether attention would be better 
focused on boosting the campaigns known to stimulate mass cessation.
10
 
 It may be time to place greater value on the lived experiences of the millions of ex-smokers 
who have successfully quit smoking, particularly in recent years. A 2013 national Gallup poll reported 
that only 8% of ex-smokers attributed their success to NRT patches, gum or prescribed drugs.
11
 In 
contrast, 48% attributed their success to quitting “cold turkey” and 8% to willpower, commitment or 
“mind over matter”. Nearly 40 years earlier, a 1974 Gallup survey reported that most smokers would 
not attend formal cessation programs and preferred to quit on their own.
6
 Unassisted cessation has 
always been both the most preferred way of quitting and the method used by most ex-smokers on 
their final, successful quit attempt, yet quitting unassisted is routinely denigrated as being not 
“evidence based”. 
 3 
 The 1964 US Surgeon General's Report kick-started the first significant and sustained period 
of antismoking activity and public consciousness of smoking and health issues. Compared with today’s 
plethora of comprehensive tobacco control policies, the subsequent smoking exodus was driven by 
only a handful of anti-smoking policies. For many smokers, having a reason to quit (a why) was more 
important than having a method to quit (a how). The key may therefore be to focus on motivating 
more smokers to try to quit and to try to quit more frequently, regardless of whether these quit 
attempts are assisted or unassisted.  
A recent review attempting to shed light on the apparent failure of contemporary obesity prevention 
policy and practice concluded that the fundamental flaw in obesity research is that ‘medicine today is 
taught untethered from its history’.
12
 Smoking cessation, in looking to its future, should not forget the 
ever-repeated important lessons from its past. 
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